Keith Newton's departure as Chief Executive Officer of Concentra Group Holdings Parent, Inc. was reported, effective November 1, 2026; the filing names no successor. As of November 10, 2026, Concentra Group Holdings Parent, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 14, 2026 to November 9, 2026, naming 2 departures (Form 8-K, August 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Concentra Group Holdings Parent, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-09
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-08
- · In / out: Out · Person: Keith Newton · Role: Chief Executive Officer · Effective: 2026-11-01 · 8-K, 2026-08-06
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-10
- · In / out: Out · Person: John Anderson · Role: Chief Medical Officer · Effective: 2026-12-31 · 8-K, 2026-04-14
Concentra Group Holdings Parent, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-14 to 2026-11-09. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Concentra Group Holdings Parent, Inc. files it.
Also on the record for Concentra Group Holdings Parent, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 1, 2026 | Stake report, Schedule 13D/A, by Robert A. Ortenzio | 5.2% of the class | 5%+ stakes | Source |
| August 24, 2026 | Stake report, Schedule 13D/A, by Robert A. Ortenzio | 5.3% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 13.7% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.32% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 13.1% of the class | 5%+ stakes | Source |
| November 26, 2025 | Stake report, Schedule 13D/A, by ORTENZIO ROBERT A | 6.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 13.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 4.9% of the class | 5%+ stakes | Source |
| July 7, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 10.28% of the class | 5%+ stakes | Source |
| July 26, 2024 | IPO filing, Form 424B4 | $23.5 a share | IPO filings | Source |
| July 24, 2024 | IPO filing, Form S-1/A | $23 to $26 a share | IPO filings | Source |
Selling to them or working with them? See who runs Concentra Group Holdings Parent, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Concentra Group Holdings Parent, Inc. and the records around it.
Concentra Group Holdings Parent, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Who owns it
Companies that share a holder
- Robert A. Ortenzio also filed stake reports on 1 other company: SELECT MEDICAL HOLDINGS CORP (Jul 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
Watch Concentra Group Holdings Parent, Inc.
Get an email when Concentra Group Holdings Parent, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Concentra Group Holdings Parent, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Concentra Group Holdings Parent, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Concentra Group Holdings Parent, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-09 | Reported | not named in the filing | 8-K, 2026-11-09 | ||
| 2026-09-08 | Reported | not named in the filing | 8-K, 2026-09-08 | ||
| 2026-08-06 | Out | Chief Executive Officer | 2026-11-01 | 8-K, 2026-08-06 | |
| 2026-07-10 | Reported | not named in the filing | 8-K, 2026-07-10 | ||
| 2026-04-14 | Out | Chief Medical Officer | 2026-12-31 | 8-K, 2026-04-14 |
Who leads Concentra Group Holdings Parent, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: John Anderson, departure reported, effective 2026-12-31 (filed 2026-04-14). No successor is named in these filings.
- Chief Executive Officer: Keith Newton, departure reported, effective 2026-11-01 (filed 2026-08-06). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Concentra Group Holdings Parent, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Concentra Group Holdings Parent, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Concentra Group Holdings Parent, Inc.Every change, in the filing's words
Reported
As previously announced, effective November 1, 2026, (i) Matthew DiCanio, the President and Chief Financial Officer of Concentra Group Holdings Parent, Inc. (the "Company"), began service as the Company's President and Chief Executive Officer, (ii) William K. Newton transitioned from Chief Executive Officer of the Company to serve as the Executive Chairman of the Company's Board of Directors (the "Board") and (iii) Tanner Newton began service as the Company's Executive Vice President and Chief Financial Officer.
- On November 4, 2026, Concentra Health Services, Inc., a wholly owned subsidiary of the Company ("CHSI"), entered into the following employment agreements, each effective November 1, 2026.
- Employment Agreement with Matthew DiCanio CHSI, on behalf of itself and the Company, entered into an Amended and Restated Employment Agreement with Mr. DiCanio (the "DiCanio Agreement").
- The DiCanio Agreement amends and restates Mr. DiCanio's existing employment agreement in its entirety and continues until terminated in accordance with its terms.
- The DiCanio Agreement provides that Mr. DiCanio will serve as President and Chief Executive Officer of the Company and will report to the Board.
- While Mr. DiCanio remains Chief Executive Officer, the Board will nominate Mr. DiCanio for election as a director at each applicable annual meeting of stockholders.
- Among other things, the DiCanio Agreement provides for (i) an annual base salary of $785,000, (ii) an annual target bonus of 125% of base salary and (iii) Mr. DiCanio's participation in the Company's employee benefit plans.
- If such termination occurs within the period beginning three months before and ending 12 months after a "Change in Control" (as defined in the DiCanio Agreement), (i) the salary continuation period increases to 30 months and (ii) all outstanding unvested equity awards vest in full.
Reported
As previously announced, effective November 1, 2026, (i) Matthew DiCanio, the President and Chief Financial Officer of Concentra Group Holdings Parent, Inc. (the "Company"), will serve as the Company's President and Chief Executive Officer and (ii) Keith Newton will transition from Chief Executive Officer of the Company to serve as the Executive Chairman of the Company's Board of Directors ("Board").
- On September 8, 2026, the Company announced the appointment of Tanner Newton as Executive Vice President and Chief Financial Officer of the Company, effective November 1, 2026 (the "Effective Date").
- Mr. T. Newton, age 34, currently serves as the Company's Senior Vice President, Strategy & Finance, a position he has held since January 2025.
- Prior to joining the Company, Mr. T. Newton served as a Principal at Tailwater Capital LLC, a Dallas-based private equity firm, from January 2017 to January 2025.
- Prior to joining Tailwater Capital LLC, Mr. T. Newton served as Investment Banking Analyst at Piper Sandler & Co., an investment bank, from July 2014 to January 2017.
- Mr. T. Newton holds a Master of Science in Finance from Texas A&M University and a Bachelor of Business Administration, Accounting and Business Honors from Texas A&M University.
- Mr. T. Newton is the son of Mr. K. Newton, a member of the Board and the Company's current Chief Executive Officer.
Departing: Keith Newton, Chief Executive Officer, effective 2026-11-01
On August 4, 2026, Keith Newton, Chief Executive Officer of the Company and member of the Company's Board of Directors (the "Board"), notified the Board of his intent to resign from the role of Chief Executive Officer, effective November 1, 2026, and transition to Executive Chairman of the Board.
- Additionally, Robert Ortenzio, the Chair of the Board, has notified the Board of his intent to resign from the role of Chair of the Board while continuing to serve as a director of the Board, effective as of November 1, 2026.
- In connection with this transition, on August 5, 2026, the Board approved the addition of one seat to the Board and appointed Matthew DiCanio, who currently serves as President and Chief Financial Officer, to succeed Mr. Newton as (i) President and Chief Executive Officer and (ii) a Class III director of the Board, both effective as of November 1, 2026.
- The Company expects to announce its chief financial officer succession plan prior to the leadership transition taking effect on November 1, 2026.
Reported
If Dr. Anderson is terminated for Cause or voluntarily resigns prior to the expiration of the Term, all of Dr. Anderson's unvested equity awards will be immediately forfeited.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers.
- Consulting Agreement As previously disclosed, on April 10, 2026, Dr. John R. Anderson notified Concentra Group Holdings Parent, Inc. (the "Company") of his retirement from his position as Executive Vice President and Chief Medical Officer of the Company effective as of December 31, 2026.
- In connection with Dr. Anderson's retirement, on July 6, 2026, Concentra Health Services, Inc., a subsidiary of the Company ("Concentra"), and Dr. Anderson entered into a consulting agreement, pursuant to which Dr. Anderson will serve as an independent contractor providing part-time consulting services to Concentra following his retirement (the "Consulting Agreement").
- The Consulting Agreement becomes effective on January 1, 2027 (the "Effective Date") and has a term through December 31, 2027 (the "Term"), unless earlier terminated.
- Either party may terminate the Consulting Agreement at any time upon 30 days' prior written notice to the other party.
- Concentra may terminate the Consulting Agreement immediately for Cause (as defined in Dr. Anderson's Employment Agreement with Concentra dated November 19, 2010, as amended).
Departing: John Anderson, Chief Medical Officer, effective 2026-12-31
Chief Medical Officer Departure On April 10, 2026, Dr. John Anderson notified Concentra Group Holdings Parent, Inc. (the "Company") of his retirement from his position as Executive Vice President and Chief Medical Officer of the Company effective as of December 31, 2026.
- The Company expects to enter into a Consulting Agreement with Dr. Anderson to support the transition of his responsibilities following his retirement.
Tools for this story
Each opens in a new tab, filled in for Concentra Group Holdings Parent, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.